Compare NDAQ & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | EW |
|---|---|---|
| Founded | 1971 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7B | 45.5B |
| IPO Year | 2002 | 2000 |
| Metric | NDAQ | EW |
|---|---|---|
| Price | $90.06 | $86.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $101.71 | $94.68 |
| AVG Volume (30 Days) | 2.6M | ★ 3.5M |
| Earning Date | 10-21-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 66.50 | N/A |
| EPS | ★ 2.80 | 2.33 |
| Revenue | ★ $8,168,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | N/A | $14.26 |
| Revenue Next Year | $7.75 | $9.77 |
| P/E Ratio | ★ $32.22 | $37.70 |
| Revenue Growth | ★ 16.40 | 10.60 |
| 52 Week Low | $64.84 | $65.94 |
| 52 Week High | $97.63 | $87.89 |
| Indicator | NDAQ | EW |
|---|---|---|
| Relative Strength Index (RSI) | 58.50 | 59.20 |
| Support Level | $87.79 | $83.60 |
| Resistance Level | $91.26 | $87.40 |
| Average True Range (ATR) | 1.52 | 1.76 |
| MACD | 0.31 | -0.28 |
| Stochastic Oscillator | 83.85 | 63.57 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.